Medical - Devices · NYSE
当前价格
$69.17
内在价值
使用下方计算器估算
对 Boston Scientific Corporation 运行 PE 市盈率估值，自动填充盈利数据，可调节目标 PE，即时获得公允价值估算。
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Earnings Yield
2.82%
ROE (TTM)
12.5%
基于过去 12 个月的数据，BSX 每股收益为 N/A，市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
BSX 的过去 12 个月市盈率反映投资者为 Boston Scientific Corporation 每一美元收益所支付的价格。该指标在与Medical - Devices同类公司和公司自身历史区间对比时最有意义。
BSX 是否被高估取决于将其市盈率与Medical - Devices同类公司、历史均值和增长预期比较。高于行业均值的 PE 可能暗示高估，但高增长公司通常有更高的估值倍数。建议配合 DCF 模型获得更完整的判断。
对 Boston Scientific Corporation 使用 PE 估值的步骤：(1) 将当前市盈率与Medical - Devices中位数对比评估相对定价，(2) 查看 PEG 比率以调整增长预期，(3) 参考 5 年 PE 历史区间判断当前位置，(4) 用目标 PE 乘以前瞻 EPS 估算公允价值。这种相对估值方法与 DCF 的绝对估值互为补充。
PEG 比率将市盈率除以预期盈利增速，提供增长调整后的估值指标。PEG 低于 1.0 可能表明相对于增长被低估，高于 2.0 可能暗示高估。PEG 对盈利增长稳定可预测的公司最为可靠。
PE 市盈率给出快速的相对定价——BSX 相对于Medical - Devices同类的估值水平。DCF 基于预期自由现金流提供绝对价值。建议用 PE 做快速筛选，用 DCF 做深度分析。两种方法各有盲区：PE 忽略了资本结构和现金流质量，DCF 则对增长率和折现率假设非常敏感。
